Most cancer drugs that kill tumors also damage healthy tissue. That is not a flaw in the design — it is the fundamental problem that oncology has been trying to solve for decades. And it is the problem that Stipple Bio, a Cambridge-based biotechnology company that emerged from stealth this week with a heavily oversubscribed $100 million Series A, believes it has a genuinely new approach to solving.
The round was co-led by three of the most serious investors and venture capital firms in life sciences: RA Capital Management, Andreessen Horowitz’s Bio+Health fund, and Nextech Invest. Existing backers including Google Ventures, Emerson Collective Investments, and LoLa Capital Partners also participated. The company says the funding should carry it through 2029 — enough runway to take its lead drug candidate, STP-100, into clinical trials and continue building out a broader pipeline.
The science behind Stipple Bio starts with a question that sounds deceptively simple: what exactly makes a cancer cell different from a normal cell at the surface level? Most precision oncology approaches look at gene expression — which genes are turned on or off in tumor cells versus healthy ones. Stipple Bio’s founders, Dr. Aaron Ring of Fred Hutch and Dr. Aashish Manglik of UCSF, both professors and pioneers in cancer biology, believed that approach leaves important information on the table. They wanted to go one level deeper, to the epitope — the specific molecular shape on a protein’s surface that an antibody actually binds to.
The distinction matters enormously. Many proteins are expressed in both tumor cells and normal tissue. An antibody targeting a protein based on its presence alone risks attacking healthy cells too — what the field calls on-target, off-tumor toxicity. It is one of the most persistent problems in antibody drug conjugate development, a class of therapies described as “biological missiles” that deliver toxic payloads directly to cancer cells via antibody guidance. The FDA has now approved 15 ADCs, but clinical experience has shown that when an antibody target appears in normal tissue as well, patients pay for it in side effects. Some candidates have been discontinued entirely after severe toxicities emerged.
Stipple Bio’s Pointillist Platform — named after the painting technique that builds a complete image from individual dots of color — maps tumor-specific epitopes at a resolution the company calls “molecular pixel” level. The idea is that even if a protein appears in both a tumor cell and a healthy cell, the exact shape and accessibility of a specific site on that protein might be unique to the tumor. Find that site, build a binder that targets it exclusively, and you can theoretically treat cancer while leaving healthy tissue untouched.
STP-100, the company’s lead candidate, is an ADC built on exactly this logic. The drug incorporates tumor-specific binders designed to avoid the on-target, off-tumor problem that has tripped up other ADCs in the same class. The plan is to file an Investigational New Drug application with the FDA and enter early-stage clinical trials in early 2027.
Founding CEO Jeff Landau said the goal is to build a modality-agnostic pipeline — meaning the Pointillist Platform is not locked to ADCs specifically. In principle, the same epitope-mapping approach could inform other therapeutic modalities as they mature. The company is using a portion of the Series A to identify additional tumor-specific targets beyond whatever STP-100 addresses, expanding the pipeline while the lead candidate moves toward the clinic.
What makes the $100 million raise notable is not just the size — though for a stealth-stage company with one named clinical-stage candidate, it is substantial — but who oversubscribed it. RA Capital and a16z Bio+Health do not lead nine-figure rounds based on narrative alone. Both firms have been invested since the seed stage, which means they have had years to evaluate the underlying science before committing this level of capital publicly.
Near Boston, where Takeda just cut 250 more Kendall Square jobs and the broader biotech correction has been grinding for two years, a $100 million Series A out of stealth is a reminder that the region’s innovation pipeline does not stop moving just because the market cycle is difficult. The companies that get built in the hard years tend to be the ones worth watching when things turn.
Stipple Bio was founded in 2022. If the clinical data holds, 2027 is when the real test begins.
